Prasugrel is primarily used as an antiplatelet medication to prevent blood clots in patients with acute coronary syndromes who are undergoing percutaneous coronary intervention (PCI), such as stent placement. It works by inhibiting platelet aggregation, reducing the risk of thrombotic cardiovascular events like heart attacks and strokes. This medication is particularly beneficial for patients with a history of heart conditions or those at high risk of arterial blockages. It is often prescribed in combination with aspirin to enhance its effectiveness. Prasugrel is typically administered in a hospital setting or under strict medical supervision due to its potent effects and potential bleeding risks. It is not recommended for patients with a history of stroke or transient ischemic attack (TIA) due to the increased risk of bleeding complications.